Tomo-seq identified SOX9 as a key regulator of cardiac fibrosis during ischemic injury, with colocalization of SOX9 and COL1 confirmed in patients with ischemic heart disease.
Tomo-seq identified SOX9 as a key regulator of cardiac fibrosis during ischemic injury, highlighting it as a potential therapeutic target for preventing pathological remodeling.
BACKGROUND: Cardiac ischemic injury induces a pathological remodeling response, which can ultimately lead to heart failure. Detailed mechanistic insights into molecular signaling pathways relevant for different aspects of cardiac remodeling will support the identification of novel therapeutic targets. METHODS: Although genome-wide transcriptome analysis on diseased tissues has greatly advanced our understanding of the regulatory networks that drive pathological changes in the heart, this approach has been disadvantaged by the fact that the signals are derived from tissue homogenates. Here we used tomo-seq to obtain a genome-wide gene expression signature with high spatial resolution spanning from the infarcted area to the remote to identify new regulators of cardiac remodeling. Cardiac tissue samples from patients suffering from ischemic heart disease were used to validate our findings. RESULTS: blunted the cardiac fibrotic response on ischemic injury. The colocalization between SOX9 and COL1 could also be confirmed in patients suffering from ischemic heart disease. CONCLUSIONS: Based on the exact local expression cues, tomo-seq can serve to reveal novel genes and key transcription factors involved in specific aspects of cardiac remodeling. Using tomo-seq, we were able to unveil the unknown relevance of SOX9 as a key regulator of cardiac fibrosis, pointing to SOX9 as a potential therapeutic target for cardiac fibrosis.
Lacraz et al. (Thu,) conducted a other in Ischemic heart disease. Tomo-seq was evaluated on Identification of regulators of cardiac remodeling. Tomo-seq identified SOX9 as a key regulator of cardiac fibrosis during ischemic injury, with colocalization of SOX9 and COL1 confirmed in patients with ischemic heart disease.